{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"524"},{"groupId":"OG002","value":"93"}]}],"title":"With Treatment-Emergent Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"39"}]}],"title":"With Treatment-Emergent Serious Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"542"},{"groupId":"OG001","value":"540"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"},{"description":"Participants received initially placebo along with prednisone 5 mg tablet, orally, later on switched to 1,000 milligram (mg) abiraterone acetate tablet (as 4\\*250 mg tablets) along with prednisone 5 mg tablet due to disease progression.","id":"OG002","title":"Placebo to Abiraterone Acetate"}],"paramType":"NUMBER","populationDescription":"Safety analysis set included all participants in the randomized population who received any study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 30 days after the last dose of study drug","title":"Number of Participants With Treatment Emergent Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}